Clearmind Medicine Inc. (NASDAQ: CMND) and Polyrizon Ltd. (NASDAQ: PLRZ) entered into a development agreement on February 6 2026 to apply Polyrizon’s proprietary intranasal hydrogel platform to Clearmind’s lead compound, MEAI. The collaboration aims to produce a nasal spray that improves bioavailability and delivers the drug directly to the brain, potentially accelerating clinical validation for addiction‑related and other central nervous system disorders.
Polyrizon’s hydrogel technology, which incorporates its “Capture and Contain” and “Trap and Target” platforms, is designed to increase nasal residence time and target delivery to specific brain regions. By integrating this technology with MEAI, Clearmind seeks to bypass first‑pass metabolism and achieve higher central nervous system exposure at lower doses, a key advantage for a non‑hallucinogenic neuroplastogen.
The partnership represents a strategic shift for Clearmind, expanding its delivery modalities beyond oral dosing and positioning the company to address unmet needs in addiction and mental health treatment. A more efficient intranasal formulation could shorten the time to therapeutic effect, improve patient adherence, and broaden the therapeutic reach of MEAI across multiple indications.
The agreement is a related‑party transaction, and the financial terms—including upfront payments, milestone payments, and royalty structures—were not disclosed. Polyrizon’s stock has experienced significant volatility in the past year, while Clearmind’s financial health remains modest, with a negative EBITDA and limited cash reserves. The lack of disclosed financial terms underscores the need for future funding to support the development program.
CEO Dr. Adi Zuloff‑Shani said, “Partnering with Polyrizon to develop an intranasal formulation for MEAI complements our efforts to optimize delivery, potentially improving bioavailability and therapeutic efficacy for our non‑hallucinogenic neuroplastogen candidates.” The quote highlights Clearmind’s confidence that the collaboration will enhance the clinical profile of MEAI.
Polyrizon’s hydrogel platform has been explored for other applications, such as intranasal naloxone for opioid overdose reversal, indicating a broader potential for the technology. While the market reaction to the announcement has not been reported, the partnership could provide a boost to Polyrizon’s valuation by demonstrating a concrete therapeutic use case for its platform.
The development agreement positions Clearmind to accelerate regulatory approval and market entry for future MEAI‑based therapies. By combining proprietary chemistry with advanced intranasal delivery, the company aims to create a more effective and patient‑friendly treatment option for CNS disorders, potentially reshaping its competitive moat in a rapidly evolving therapeutic space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.